UNSPSC 51111744: Galarubicin

This classification denotes an anthracycline antibiotic with the molecular formula C30H32FNO13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6F39648E92, chemically known as (8s,10s)-10-((2.6-dideoxy-2-fluoro-alpha-l-talopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione 8(2)-ester with beta-alanine. but generally known as galarubicin, which bears US NIH Compound Identifier 219086.

UNSPSC 51111744 Galarubicin, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical designation. The four recent opportunities posted under this code span naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical supplies, and generic multi-source pharmaceuticals—none of which are galarubicin or closely related oncology agents. State and local buyers tagging opportunities to this code appear to be using it as a catch-all for pharmaceutical procurement rather than sourcing the specific compound. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). None of these solicitations recur under the code, and the mix suggests fragmented, episodic demand rather than sustained procurement in this category.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: due date predates posting date, indicating data quality issues in the source). The City of Tampa issued IFB 26P00145 on March 25, 2026, for medical and first aid supplies totaling an estimated $700,000 for the Tampa Fire Department, with a March 13, 2026 deadline and a five percent small-local-business-enterprise (SLBE) bid discount capped at $10,000. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment capabilities—a market-research phase preceding formal solicitation. MMCAP released RFP S1070000015802 on January 20, 2026, to establish generic pharmaceutical contracts across participating states and local entities, with proposals due March 26, 2026. The code shows no meaningful alignment with galarubicin procurement; vendors should verify whether opportunities posted under this code actually match their service or product line before investing in pursuit.